- Home
- GNW vs DYN Comparison
GNW vs DYN Comparison
Compare GNW & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNW | DYN |
|---|---|---|
| Founded | 1871 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNW | DYN |
|---|---|---|
| Price | $9.23 | $20.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 17 |
| Target Price | $10.00 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 4.3M | 3.5M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.86 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $7,299,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.99 | $6.36 |
| 52 Week High | $9.23 | $26.22 |
Technical Indicators
Market Signals| Indicator | GNW | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 71.41 | 54.66 |
| Support Level | $8.79 | $18.43 |
| Resistance Level | $9.23 | $19.86 |
| Average True Range (ATR) | 0.17 | 1.40 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 97.12 | 44.70 |
Price Performance
Historical ComparisonAbout GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.